Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide


  1. 1. CURRICULUM VITAE Name: Robert L. Martuza, M.D. Office Address: Higgins Professor of Neurosurgery Chief, Neurosurgery Service Massachusetts General Hospital WHT502 55 Fruit Street, Boston, MA. 02114-2696 Phone: 617-726-8581 Fax: 617-726-4814 Email: Place of Birth: Wilkes-Barre, PA (USA) Date of Birth: July 1, l948 Education: 1969 B.A. Bucknell University, Lewisburg, PA 1973 M.D. Harvard Medical School, Boston, MA Postdoctoral Training: Internship and Residencies: 1973-1974 Intern in General Surgery, Massachusetts General Hospital, Boston, MA 1975-1979 Resident in Neurosurgery, Massachusetts General Hospital, Boston, MA 1979-1980 Chief Resident in Neurosurgery, Massachusetts General Hospital, Boston, MA Research Fellowships: 1972-1973 Student Research Fellow in Virology (Tumor virology; Dr. Paul Black), Massachusetts General Hospital 1974-1975 Clinical and Research Fellow in Neurosurgery Neurosurgical Oncology, Massachusetts General Hospital Licensure and Certification: 1976 Massachusetts Medical License Registration (39007; issued 1/30/76) 1983 American Board of Neurological Surgeons (Board certified, May l983) 1985 Fellow, American College of Surgeons Academic Appointments: 1
  2. 2. 1980-1981 Instructor in Surgery, Harvard Medical School 1981-1986 Assistant Professor of Surgery, Harvard Medical School 1986-1991 Associate Professor of Surgery, Harvard Medical School 1991-2000 Professor and Chairman, Department of Neurosurgery, Georgetown University 2000-present Higgins Professor of Neurosurgery, Harvard Medical School Hospital Appointments: 1980-1981 Assistant in Neurosurgery, Massachusetts General Hospital 1981-1986 Assistant Visiting Neurosurgeon, Massachusetts General Hospital 1987-1991 Associate Visiting Neurosurgeon, Massachusetts General Hospital 1991-2000 Professor and Chairman, Department of Neurosurgery, Georgetown University Hospital 2000-present Chief, Neurosurgery Service, Massachusetts General Hospital Other Professional Positions and Major Visiting Appointments: 1980-1991 Director, Neurofibromatosis Clinic, Massachusetts General Hospital 1988-1991 Co-director, MGH Brain Tumor Center 1992-2000 Director, Georgetown Brain Tumor Center 1999-2000 Associate Director for Clinical Research Lombardi Cancer Center, Georgetown University 2000-present Director, Pappas Center for Neuro-Oncology, MGH 2005-present Board of Trustees, Massachusetts General Physicians Organization, Inc. Principal Clinical and Hospital Service Responsibilities: 1980-1982 Emergency Ward Committee, Massachusetts General Hospital 1980-1983 Neurosurgical Intensive Care Unit Committee Massachusetts General Hospital 1980-1983 Co-director of Neurosurgical Intensive Care Unit Massachusetts General Hospital 1981-1983 Subcommittee Review for Research Proposals, Massachusetts General Hospital 1981-1991 Cancer Affairs Committee, Massachusetts General Hospital 1981-1984 CT Subcommittee, Massachusetts General Hospital 1984-1986 Chairman, Laser Safety Committee, Massachusetts General Hospital 1987-1988 Chairman, Ad Hoc Committee on Lasers, Massachusetts General Hospital 1989-1991 General Clinical Research Center Advisory Committee, Massachusetts General Hospital 1989-1991 MGH Laser Committee 1991-2000 Georgetown Operating Room Committee 1991-2000 Georgetown Executive Faculty Committee 1991-2000 Georgetown Executive Staff Committee 2
  3. 3. 1992 Georgetown Ophthalmology Chairman Search Committee 1993 Fiscal Affairs Committee, Georgetown Faculty Practice Group 1993 Georgetown Endocrinology Chief Search Committee 1993-1998 Georgetown Space Utilization Committee 1993-1998 Georgetown, Internal Advisory Board for The Program in Cognitive and Computational Sciences 1994 Chair, Search Committee for Chair of Neuroscience Department, Georgetown University 1994-1999 Staff Appointments Committee, Georgetown University Medical Center 1999-2000 Associate Director for Clinical Research Lombardi Cancer Center, Georgetown University 2000 -present Managed Care Committee, Massachusetts General Hospital 2000-present Executive Committee on Research, Massachusetts General Hospital 2000-present Partners Research Council, Partners Healthcare 2001-present General Executive Committee, The Massachusetts General Hospital Corporation 2005 Member, Search Committee for Neurosurgical Chief, Beth Israel Deaconess Medical Center 2006-present Clinical Co-Chair, MGH Vascular Center Major Committee Assignments: National and Regional: 1981-1991 Medical Advisory Board of the National Neuro-fibromatosis Foundation, New York, New York 1983 Joint Committee on Education, Congress of Neurological Surgeons and American Association of Neurological Surgeons 1984 Member of Executive Committee, Joint Section on Tumors, Congress of Neurological Surgeons, American Association of Neurological Surgeons 1985 Subcommittee on Research of Brain Tumors, Congress of Neurological Surgeons 1986-1990 Co-Chairman of Research Advisory Board, National Neurofibromatosis Foundation 1987 Joint Subcommittee on Research, Congress of Neurological Surgeons, American Association of Neurological Surgeons 1988-1991 Joint Section on Stereotactic and Functional Neurosurgery 1989 The Academy Resident Award Committee, The American Academy of Neurological Surgery 1991 First World Health Organization Planning Conference on Neurofibromatosis, FL 1991 Planning committee for NIH Consensus Conference on Acoustic Neuroma 1991 Ethics and Human Values Committee, American Association of Neurological Surgeons 1991-1992 Co-director, Review and Update in Neurobiology for Neurosurgeons, 3
  4. 4. Woods Hole, MA 1992 Chairman, The Academy of Neurological Surgery Resident Award Committee 1993-1996 Co-Chair, Technology Assessment Committee, Society of Neurological Surgeons 1994-1997 Joint Washington Committee, Congress of Neurological Surgeons 1994-1998 Chairman, Decade of the Brain Task Force American Association of Neurological Surgeons Congress of Neurological Surgeons 1994-2000 National Cancer Advisory Board, Liaison Representative of AANS 1996 Member NIH Site Visit Team, University of Alabama, Birmingham, AL 1997-present Scientific Advisory Board, MediGene, Inc, (Neurovir, Inc.). 1998 NIH Grant Reviewer for NSD-B study section meeting on Pilot Clinical Trial Grants 1998 NIH Grant Reviewer for NCI-F study section on Training Grants in Surgery 1998-present American Society of Gene Therapy, coordinating reviewer 1998-1999 Member of NIH/NINDS Brain Tumor Genome Anatomy Project 1999-present Program Committee, American Society of Gene Therapy 1999-present Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke (NINDS) 2000-present Scientific Advisory Board, Direct Gene, Inc. 2003-present Advisory Board, CEREGENE, Inc. 2003-present Director, American Board of Neurological Surgery Professional Societies: 1980-1991 Massachusetts Medical Society 1980-present American Medical Association 1982-1991 American Society for Laser Medicine and Surgery 1982-present Congress of Neurological Surgery 1983-1991; 2000-present New England Neurosurgical Society 1983-1991 Massachusetts Neurosurgical Society 1983-present American Association of Neurological Surgeons 1985-present Fellow of the American College of Surgeons 1986-1991 The New York Academy of Sciences 1986-1991 Massachusetts Chapter, American College of Surgeons 1986-present Society for Neuroscience 1988-present The American Society for Stereotactic and Functional Neurosurgery 1988-present World Society for Stereotactic and Functional Neurosurgery 1988-present Member, Section of Surgery, Royal Society of Medicine 1989-present American Academy of Neurological Surgeons 1991-present American College of Surgeons, Washington, D.C. Chapter 1992-present Society of Neurological Surgery 1992-present D.C. Medical Society 1992-2000 Southern Neurosurgical Society 1995-present The Charles A. Dana Foundation 1997-present American Association for Cancer Research 1998-present American Society of Gene Therapy 4
  5. 5. 2000-2003 Member, Cancer Gene Therapy Committee, American Society of Gene Therapy 2002-2003 Co-chair, Program Committee, American Society of Gene Therapy Editorial Boards: 1987-89 Assistant Clinical Editor, Neurofibromatosis Research Newsletter 1989-1999 Editorial Board, Journal of Neuro-oncology 1993-present Editorial Board, Cancer Gene Therapy 1997-present Commentator, Neurologia medico-chirurgica 1997-present Editorial Board, Brain Tumor Pathology 1998-present Editorial Board, Neoplasia 1999-2005 Editorial Board, Journal of Neurosurgery 2000-present Scientific Advisory Board, Encyclopedia of Neuroscience. Awards and Honors: 1968 Phi Beta Kappa, Bucknell University 1969 Louis Robey Award, Bucknell University 1969 Cum Laude, Chemistry, Bucknell University 1973 Alpha Omega Alpha, Harvard Medical School 1973 Magna Cum Laude (thesis in a special field), Harvard Medical School 1988 Traveling Fellowship from The Royal College of Surgeons of England 1989 Von Recklinghausen’s Award for the advancement of medical sciences in the field of neuro-fibromatosis; from the National Neuro-fibromatosis Foundation 1994 Grass Award, Society of Neurological Surgeons 1998 NF, Inc. Scholar Award Funded Grants: 1982-1987 Teacher-Investigator Development Award (NS00654) “Neurofibromatosis: Cellular features, hormonal controls” 1982 Principal Investigator, National Neurofibromatosis Foundation Research Grant 1983-1986 Physician’s Recognition Award, American Medical Association 1983-1986 Principal Investigator, National Institutes of Health Grant (RO1NS20025) “Hormonal modulation of tumors of neurofibromatosis” 1985-1988 Co-investigator, National Neurofibromatosis Research Grant “DNA transfection analysis of the tumors of neurofibromatosis” (P.I., L. Jacoby) 1986-1987 Principal Investigator, Whitaker Health Sciences Fund Grant “The combined treatment of malignant brain tumors with stereo-tactically applied photodynamic therapy, hyperthermia, and ionizing radiation” 1986-1987 Principal Investigator, National Neuro-fibromatosis Foundation Research 5
  6. 6. Grant “Melanocyte growth and modulation in neuro-fibromatosis” 1986-1987 Co-investigator, National Neurofibromatosis Foundation Research Grant, “Chromosomal alterations in tumors associated with bi-lateral acoustic neurofibromatosis: a molecular genetic approach focused on chromosome 22” (P.I., B. Seizinger) 1986-1990 Principal Investigator, renewal of RO1NS20025,”Hormonal modulation of tumors of neurofibromatosis” 1987-1990 Principal Investigator “Studies of melanocytes in neurofibromatosis and tuberous sclerosis”. Neurogenetics Center Grant (PO1-NS24279) 1989 Principal Investigator “Evaluation of a two-wavelength laser in neurosurgery” subcontract via Abiomed,Inc. from National Institutes of Health 1990-1992 Principal Investigator “Genetic alteration of nervous system tumors”, project 2 of Neurogenetics Center Grant (l-PO1-NS24279) 1993-1996 Principal Investigator “Molecular targeting of therapy for nervous system tumors”. (P20-CA60176-01) 1994.1997 Co-Investigator, “Gene delivery to the CNS to modulate epilepsy” (S. Rabkin, PI)(R01 NS 33342) 1994-1998 Principal Investigator “National CNS Tumor Consortium - Georgetown/Lombardi Cancer Center” (U01 CA62454) 1994-1998 Principal Investigator, “Genetically engineered viruses for brain tumor therapy” (R01 NS 32677) 1994.1998 Co-investigator, “Early clinical trials of antiangiogenesis agents” M. Hawkins, PI (U01 CA62500) 1996.1999 Principal Investigator, subcontract, 3-D Aids to stereotactic brain cancer surgery (R44 NS32610-03) 1997-1999 Principal Investigator, Pre-clinical studies of G207 (Neurovir, Inc.) 1997-2002 Program Leader, Neuro-oncology, Cancer Center Support Grant, M.Lippman, PI 1998.2000 Co- Investigator, A dose escalating Phase I Study of the treatment of Malignant Gliomas with G207, a genetically engineered HSV-1 (Neurovir, Inc.) 1998-2001 Principal Investigator, “Herpes vectors for prostate cancer therapy” CaPCURE Foundation 1998-2003 Principal Investigator, “Herpes virus therapy of prostate cancer”, Dept. of Defense (DAMD17-98-1-8490) 1998-2007 Principal Investigator, “Genetically engineered viruses for brain tumor therapy” (R01 NS 32677 -12) 2001-2006 Principal Investigator, “Clinical Research Training Program in Neuro-Oncology”, National Cancer Institute, (K12-CA90354) 2004-2007 Principal Investigator, “Immunologic Approaches for Oncolytic Viral Therapy of Prostate Cancer”, Department of Defensive (Idea Development Award) (W8IXWH-04-1-0254) 2004-2007 Principal Investigator, “HSV Vector Therapy for NF2 Lesions in Mouse Models” Department of Defense (Therapeutic Development Award) (W8IXWH-04-1-0237 ) 2004-2009 Principal Investigator, “ Genetically engineered viruses for prostate 6
  7. 7. cancer therapy” (CA102139) Major Research Interests: 1. Central Nervous System Tumors: Alteration or destruction of tumor cells by genetically engineered viruses. Studies of etiology, modulation, and treatment of nervous system tumors. Use of biologic modifiers, gene and viral therapy to treat nervous system tumors. 2. Neurofibromatosis: Clinical aspects; pathogenesis of the meningeal, Schwann cell and glial tumors. Experimental therapeutics using anti-angiogenesis agents and “nerve-sparing” viral vectors. 3. Cancer Therapy with Viral Vectors: Development of HSV1-derived vectors to treat prostate and other cancers. Development of “nerve-sparing vectors” for cancer therapy and viral vectors and cell- specific vectors as oncolytic agents and as in situ anti-cancer vaccines. 4. Molecular Neurosurgery: Use of viral vectors and genetically engineered cells for gene transfer in vitro and in vivo in order to alter nervous system function and treat intrinsic nervous system and neuro- vascular diseases. Teaching Experience: 1976 Developed and directed a continuing neuro-pathology course for neurosurgery residents 1980 Instructor in Surgery for Introduction to the Clinic for Harvard Medical Students 1981-1989 Developed and instructed a lecture and dissection course in neuroanatomy and peripheral nerve surgery for neurosurgery residents 1983 Developed and directed with the National Neurofibromatosis Foundation a symposium for physicians and associated health care persons. “Neurofibromatosis: Clinical care research directions”. 1980-1990 Lecturer, MGH Neurosurgery Post-graduate Course 1990 Organizer, moderator, speaker in section on malignant brain tumors MGH Neurosurgery Post-graduate Course 1993 Lecturer, Frontiers in Medicine Georgetown Physiology Graduate Lecture Series 1995 Lecturer, Neuroscience Survey Course 1996-1999 Medical student lectures on neurosurgery, Georgetown 1998-1999 Medical student and Neurology resident lectures on CNS tumors 1998-1999 Lecturer, Neuroscience Survey Course, Georgetown University Invited Lectures and Visiting Professorships 1981 Invited lecturer “Lasers and phototherapy in Neurosurgery”, Mayo Clinic 1984 Invited lecturer, CT Stereotactic-Surgery, Sponsored by: Division of Neurosurgery, University of Utah School of Medicine 1987 Invited Guest Speaker, First LINK Conference on Neurofibromatosis, Runnymeade, England1987-1993 Invited lecturer at Woods Hole course “Review and Update in Neuroscience for Neurosurgeons” 7
  8. 8. 1988 Visiting Professor and lecturer, The Royal Hallamshire Hospital, Sheffield, England 1988 Visiting Fellow and Lecturer, The Frenchay Hospital, Bristol, England 1988 Visiting Fellow and Lecturer, The Midland Centre for Neurosurgery, Birmingham, England 1988 Visiting Fellow and Lecturer, Radcliffe Infirmary, Oxford, England 1989 Invited Speaker and Session Chairman, First Meeting of the International Society on Neurocutaneous Disorders, Tokyo, Japan 1989 Invited Guest Speaker, The American Academy of Neurological Surgery, Tuscon 1989 Visiting Professor, Chicago Neurosurgical Center 1990 Visiting Professor, Dartmouth Medical School 1990 Organizer and speaker, First MGH Brain Tumor Workshop 1990 Invited Speaker, Banbury Conference on Neurofibromatosis, Cold Spring Harbor, NY 1990 Guest Speaker, American Neurological Association, Atlanta 1990 Invited Guest Speaker, 8th Nikko Brain Tumor Conference, Saga, Japan 1991 Co-director, Woods Hole course “Review and Update in Neuroscience for Neurosurgeons” 1991 Browder Memorial Lecture, New York Neurosurgical Society 1992 Arkin Memorial Lectureship, Chicago Children’s Hospital 1992 Invited Guest Speaker, LINK Conference on Neurofibromatosis, Oxford, U.K. 1992 Invited speaker, American Academy of Neurological Surgeons 1992 Invited Guest Speaker, 5th Canadian Neuro-Oncology Meeting 1992 First Visiting Professor, Carolyn Farb Endowment Fund in Neurofibromatosis, M.D. Anderson Cancer Center 1992 Invited speaker, Preuss Foundation Seminar, Miami Beach 1993 Invited speaker, Decade of the Brain Symposium “Advances in the Treatment of Brain Tumors”, Univ. Cincinnati 1993 Invited guest lecturer, Japan Neurosurgery Society, Tokyo Visiting Professor, Asian Medical Center, Seoul, Korea 1993 Galbraith Lectureship and Visiting Professor, University of Alabama 1993 Janssen Distinguished Lecturer, “Current concepts in brain tumor biology and therapy”, 21st Annual Meeting, SNACC, Washington, DC 1993 Invited speaker, Second Conference on Cancer Gene Therapy, San Diego 1993 Invited Lecturer, UCLA post-graduate update on brain tumor therapy, Los Angeles 1993 Invited speaker, Scandinavian Glioma Conference, Copenhagen 1994 Visiting Professor, Emory University 1994 Altman Lecturer, University of Pennsylvania 1994 Keith Visiting Lectureship, University of Toronto 1994 Visiting Professor and guest lecturer University of Chicago 8
  9. 9. 1994 Chairman and lecturer Decade of the Brain Symposium “Gene Therapy in the Nervous System” 1994 AANS meeting, San Diego 1994 Invited speaker, Preuss Foundation Seminar on Tumor markers for glial tumors, San Diego CA 1994 Invited speaker, Grass Award Lecture, Society of Neurological Surgeons, Charlottesville, VA 1994 Invited Lecturer, 7th Canadian Neuro-oncology Meeting, Calgary 1994 Guest speaker, Canadian Congress of Neurological Sciences, St. Johns, Newfoundland 1994 Session leader and guest speaker, Therapeutic approaches to neurofibromatosis, FASEB conference on neurofibromatosis, Santa Cruz, CA 1994 Aitken Memorial Lecture, London, Ontario 1994 Invited speaker, Brain Tumor Symposium on New Therapies, Hutchinson Cancer Center, Seattle 1994 Invited speaker, Taxin Brain Tumor Symposium, Wistar Institute, Philadelphia, PA 1995 Neuro-oncology Lectureship Visiting Professor, Mayo Clinic 1995 Lecturer, Gene Therapy Series, National Institutes of Health 1995 Invited Speaker and Scientific Committee Member Gene Therapy for CNS Disorders, Univ. of Pennsylvania, Philadelphia, PA 1995 Session Leader and invited speaker, NNFF International Consortium for Molecular Biology of NF1 and NF2, Philadelphia, PA 1995 Invited Speaker, “Development of replication competent viruses for therapy of brain tumors” at the “International Symposium of Molecular Neurosurgery Based on Gene Therapy” Nagoya, Japan 1995 Invited Speaker and Chair of Gene Therapy Session, The Eleventh International Conference on Brain Tumor Research and Therapy, Napa, California, U.S.A. 1995 Invited Speaker, Delaware Neurosurgical Society 1996 Invited Speaker, Huntsman Cancer Center, Salt Lake City, Utah 1996 Invited speaker, Preuss Conference on Gene Therapy for Brain Tumors, San Diego, CA. 1996 Visiting Professor, Jefferson Medical College, Philadelphia, PA 1996 Invited lecturer, Univ. Michigan Cancer Center, Ann Arbor, MI 1996 Invited lecturer, Univ. So. Carolina, Charleston, SC 1996 Chair, AANS Decade of the Brain Symposium, “Watching the Brain Work”, Minneapolis, Minn. 1996 Invited Speaker and Moderator of section onCNS Gene Therapy, TIGR Gene Therapy Conference, Hilton Head, NC 1996 Chair, Section on Experimental Therapeutics for NF, FASEB Conference on NF, Aspen, CO 1996 Visiting Professor, Henry Ford Hospital, Detroit, MI 1996 Invited speaker, FDA/NIH conference on Gene Therapy, Bethesda, MD 1997 Pennathur Sundarum Memorial Lecturer, Herpes Virus Therapy of Cancer, Massachusetts General Hospital, Boston 1997 Invited Speaker, NIH Conference on Herpes Vectors 1997 Visiting Professor, Wake Forest University Medical Center (formerly 9
  10. 10. Bowman-Gray Medical School) 1997 Invited Lecturer, New York University post graduate course, “A Systems Approach to Glial Neoplasms” 1997 Speaker and symposium moderator, “State of the Art Treatment of Brain Tumors”; American Brain Tumor Association and Childhood Brain Tumor Foundation, Washington, D.C. 1997 Invited speaker, Workshop on NF2: Present and Future,Bethesda, MD 1997 Invited Lecturer, Wood’s Hole RUNN course 1998 Invited speaker, AANS Tumor Satellite Meeting, Phila., PA 1998 Invited speaker, American Society of Gene Therapy, First Annual Meeting, Seattle, WA. “Herpes virus targeting of glioblastoma” 1998 Invited speaker, First International Congress, Genetics in Neuroscience, Terni, Italy 1998 Invited speaker, CaPCURE Annual Research Retreat 1998 Invited Lecturer, Wood’s Hole RUNN course 1999 Chairman and speaker of session on “Neurocutaneous Syndromes”, Congress of Neurological Surgeons meeting, Seattle 1998 Invited Lecturer, New York University post graduate course, “A Systems Approach to Glial Neoplasms” 1998 Invited lecturer, Institute for Human Gene Therapy Annual Retreat, Univ. Pennsylvania 1999 Visiting Professor and Invited speaker, Johns Hopkins Medical School, Dept. Neurosurgery 1999 The First Annual Arthur and Sonia Labatt Brain Tumor Research Center Academic Lecturer, Toronto 1999 Invited speaker, Second US-Japan Gene Therapy Conference, Bethesda, MD 1999 Invited Speaker, “Conditionally replicating herpes vectors for tumor therapy”, Amer. Assoc. for Cancer Research 90th meeting, Philadelphia, PA 1999 Chair, Cancer I Session, American Society of Gene Therapy, Second Annual Meeting, Washington, DC 1999 Invited speaker, International Heresvirus Workshop, Cambridge, MA 1999 Invited Speaker, “Development of herpes vectors for cancer therapy,” National Cancer Institute Phase I Meeting, Bethesda, MD 1999 Invited presenter, CaPCURE Annual Research Retreat 1999 Visiting Professor, Saga Medical School, Saga, Japan 1999 Visiting Professor, Nagoya Medical School, Nagoya, Japan 1999 Honored Guest Speaker, 58th Japan Neurosurgical Society, Tokyo 2000 Invited Speaker, RUNN Course, Woods Hole, MA Invited Speaker, “Development of herpes vectors for abnormal prostate cancer”, CaPCURE Retreat, Lake Tahoe, Nevada 2001 Invited Speaker, Second International Symposium on Genetic Anticancer Agents, Valencia, Spain 2001 Invited speaker, CaPCURE Eighth Annual Scientific Retreat, Lake Taho, Nevada 2002 Invited Speaker, 93rd Annual Meeting, American Association for Cancer Research, San Francisco, CA 10
  11. 11. 2002 Invited Speaker and Moderator, Annual Meeting, American Association of Neurological Surgeons, Chicago, Il. 2002 Invited Speaker, 53rd Annual Meeting of the German Society of Neurosurgery, Halle/Saale, Germany 2002 Invited Speaker, Third International Symposium on Genetic Anticancer Agents, Amsterdam, The Netherlands 2002 Invited Speaker, Japan Neurosurgical Society 61st Annual Meeting, Matsumoto, Japan 2002 Keiji Sano Lectureship, Teikyo University School of Medicine, Tokyo, Japan 2002 Invited Speaker, Brain Tumor Forum, Nagoya Brain Tumor Society, Nagoya Japan 2003 Invited Speaker, Oncolytic Viruses as Cancer Therapeutics Conference, Banff, Alberta Canada 2003 Invited Speaker, 15th International Conference on Brain Tumor Research and Therapy, Sorrento, Italy 2003 Visiting Professor/Speaker, Departments of Medicine and Surgery and of Neurosurgery, “La Sapienza” (University of Rome), Policlinico Umberto I Hospital, Rome, Italy 2004 Invited speaker, Tenth Annual Meeting of the Blood-Brain Barrier Disruption Consortium, Bend, Oregon 2004 Keynote Speaker, 5th Annual Meeting of the Japan Molecular Neurosurgical Meeting, Tokyo, Japan 2004 Frank P. Smith Visiting Professor, University of Rochester Medical School, Rochester, New York 2004 Keynote Speaker, 3rd Meeting of the Asian Society for Neuro-Oncology and 3rd Shanghai International Conference of Neurosurgery (Joint Conference), Shanghai, China 2004 Invited Speaker, Beijing Tiantan Hospital and Beijing Neurosurgical Institute, Beijing, China 2005 Keynote Speaker, Japan Neurological Society, Yokohama, Japan 2005 Keynote Speaker, RUNN Course, Woods Hole, MA 2005 Lecturer, Harvard Medical School, Course on Brain Tumors, Boston, MA Inventions and Patents 1. Inhibition of neurofibrosarcoma growth and angiogenesis (patent filed 1990; patent issued July 18, 2000; # 6,090,794) 2. Viral mediated destruction of neoplastic cells (patent filed 1990) 3. Viral targeted destruction of neoplastic cells (patent filed 1990) 4. Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication (patent filed 1992) 5. Replication-competent herpes simplex-1 virus mediates destruction of neoplastic cells (patent filed 1994; patent issued Dec.17, 1996; #5,585,096) 11
  12. 12. 6. Tumor- or cell-specific herpes simplex viral replication (patent filed 1995; patent issued Mar.17, 1998; #5,728,379) 7. Use of herpes vectors for tumor therapy (application #60/055,142; filed 08/12/97) 8. Implanting HSV-TK Retrovirus Producing Cells To Treat Tumors (patent filed 1995, patent issued: 08/462,508) 9. Implantation of HSV-TK Retrovirus Producer Cells to Destroy Glioma (patent filed 1995, patent issued: 08/462,500) 10. Transfer and Expression of Gene Sequences into Nervous System Cells Using Herpes Simplex Virus Mutants with Deletions in Genes for Viral Replication (patent filed 1994, patent issued 2003 6,610,287 B1) 11. Replication-Competent Herpes Simplex Virus Mediates Destruction of Neoplastic Cells (patent filed 2000, patient issued 2004 6,699,468 B1) Bibliography Original Reports (Published and In Press) 1. Martuza RL, Black PH, Kornblith PL, Dohan FC Jr. Evidence for presence of a virus in glioblastoma multiforme cells. Surg For 1973; 24: 459-61. 2. Martuza RL, Shamberger RC, Phillips JP, Kornblith PL, Dohan FC Jr, Hochberg FH. A lymphocyte-dependent antibody assay for detection of antibodies to human glioma cells. Surg For 1975; 26: 492-4. 3. Martuza RL, Proffitt MR, Moore MB, Dohan CF Jr. Evaporation as a cause of positional differences in cell plating and growth in microtiter plates. Transplantation 1976 Mar; 2l(3): 271-273. 4. Stewart RM, Martuza RL, Baldessarini RJ, Kornblith PL. Glutamate accumulation by human gliomas and meningiomas in tissue culture. Brain Res 1976 Dec24; 118(3): 441-52. 5. Phillips JP, Sujatanond M, Martuza RL, Quindlen EA, Wood WC, Kornblith PL, Dohan FC Jr. Cytotoxic antibodies in preoperative glioma patients: A diagnostic assay. Acta Neur 1976; 35(1- 3): 43-52. 6. Martuza RL, Kornblith PL, Liszczak TM. Characteristics of human optic gliomas in tissue culture. J Neurosurg 1977 Jan; 46(1): 78-84. 7. Chapman PH, Martuza RL, Poletti CE, Karchmer AW. Symptomatic spinal epidural lipomatosis associated with Cushing’s Syndrome. Neurosurg 1981 Jun; 8(6): 724-7. 8. Martuza RL, Ojemann RG, Shillito J Jr, Wepsic JG. Facial pain associated with a middle fossa arachnoid cyst. Neurosurg 1981 Jun; 8(6): 712-16. 9. Martuza RL, MacLaughlin DT, Ojemann RG. Specific estradiol binding in schwannomas, meningiomas, and neurofibromas. Neurosurg 1981 Dec; 9(6): 665-71. 10. Martuza RL, Ojemann RG. Bilateral acoustic neuromas: clinical aspects, pathogenesis, and treatment. Neurosurg 1982 Jan; l0(1): l-l2. 11. Conner ES, Martuza RL, Heros RC. Seizures due to metrizamide myelography in patients with acute cervical spine injury. Neurosurg 1982 Feb: 10(2): 266-7. 12. Martuza RL, Liszczak T, Okun A, Wang T-Y. Human neurofibromas in co-culture with mouse neurons. 40th Ann Proc Elec Micro Soc Amer 1982: 194-195. 13. Martuza RL. Genetics in neuro-oncology. Clin NeurosSurg 1983; 31: 417-40. 14. Nakagawa H, Hori Y, Sato S, Fitzpatrick TB, Martuza RL. The nature and origin of the melanin macroglobule. J Invest Dermatol 1984; 83(2): 134-9. 15. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: Analysis of recurrence and progression following neurosurgical resection. J Neurosurg 1984 Jan; 62(1): 12
  13. 13. l8-24. 16. Granick MS, Martuza RL, Parker SW, Ojemann RG, Montgomery WW. Cerebellopontine angle meningiomas: Clinical manifestations and diagnosis. Ann Otol Rhinol Laryngol 1985 Jan-Feb; 94(1 Pt 1): 34-8. 17. Jay JR, MacLaughlin DT, Riley KR, Martuza RL. Modulation of meningioma cell growth by sex steroid hormones in vitro. J Neurosurg 1985 May; 62(5): 757-62. 18. Martuza RL, Miller DC, MacLaughlin DT. Estrogen and progestin binding by cytosolic and nuclear fractions of human meningiomas. J Neurosurg 1985 May; 62(5): 750-6. 19. Martuza RL, Phillipe I, Fitzpatrick TB, Zwaan J, Seki Y, Lederman J. Melanin macroglobules as a cellular marker of neurofibromatosis: A quantitative study. J Invest Dermatol 1985 Oct; 85(4): 347-50. 20. Kostron H, Swartz MR, Miller DC, Martuza RL. The interaction of hematoporphyrin derivative, light, and ionizing radiation in a rat glioma model. Cancer 1986 Mar 1; 57(5): 964-70. 21. Kostron H, Bellnier DA, Lin CW, Schwartz MR, Martuza RL. Distribution, retention, and phototoxicity of hematoporphyrin derivative in a rat glioma. Intraneoplastic versus intraperitoneal injection. J Neurosurg 1986 May; 64(5): 768-74. 22. Cohen AM, Wood WC, Bamberg M, Martuza R. Cytotoxicity of human brain tumors by hematoporphyrin derivative. J Surg Res 1986 Jul; 41(1): 81-3. 23. Seizinger BR, Martuza RL, Gusella JF. Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 1986 Aug 14-20; 322(6080): 644-7. 24. Bouckoms A, Martuza RL, Henderson M. Capgras syndrome with subarachnoid hemorrhage. J Nerv Ment Dis 1986 Aug; 174(8): 484-8. 25. Brockes JP, Breakefield XO, Martuza RL. Glial growth factor-like activity in Schwann cell tumors. Ann of Neurol. 20(3): 3l7-22, 1986 Sep. 26. Steichen JD, Dashner K, Martuza RL. Distribution of hematoporphyrin derivative in canine glioma following intraneoplastic and intraperitoneal injection. J Neurosurg 1986 Sep; 65(3): 364-9. 27. Jacoby L, Martuza RL. DNA transfection analysis of the tumors of neurofibromatosis. Ann NY Acad Sci 1986; 486: 333-5. 28. Jay JR, MacLaughlin DT, Badger TM, Miller DC, Martuza RL. Hormonal modulation of Schwann cell tumors. I. The effects of estradiol and tamoxifen on methylnitrosourea-induced rat Schwann cell tumors. Ann NY Acad Sci 1986; 486: 371-82. 29. Fitzpatrick TB, Martuza RL. Clinical diagnosis of von Recklinghausen’s neurofibromatosis. Ann NY Acad Sci 1986; 486: 383-5. 30. Seizinger BR, Rouleau G, Ozelius LJ, Lane AH, St. George-Hyslop P, Huson S, Gusella JF, Martuza RL. Common pathogenetic mechanism for three tumor types in bilateral acoustic neurofibromatosis. Science 1987 Apr 17; 236(4799): 317-9. 31. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Faryniarz AG, Chao MV, Huson S, Korf BR, Parry DM, Pericak-Vance MA, Collins FS, Hobbs W, Falcone BG, Iannazzi JA, Roy FC, St George-Hyslop PH, Tanzi RE, Bothwell MA, Upadhyaya M, Harper P, Goldstein AE, Hoover DL, Bader JL, Spence MA, Mulvihill JJ, Aylsworth AS, Vance JM, Rossenwasser GOD, Gaskell PC, Roses AD, Martuza RL, Breakefield XO, Gusella JF. Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell 1987 Jun 5; 49(5): 589-94. 32. Seizinger BR, de la Monte S, Atkins L, Gusella JF, Martuza RL. Molecular genetic approach to human meningioma: Loss of genes on chromosome 22. Proc Nat Acad Sci USA 1987 Aug; 84(15): 54l9-23. 13
  14. 14. 33. Rouleau GA, Wertelecki W, Haines JL, Hobbs WJ, Trofatter JA, Seizinger BR, Martuza RL, Superneau DW, Conneally PM, Gusella JF. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 1987 Sep 17-23; 329(6136): 246-8. 34. Nadol JB Jr, Levine R, Ojemann RG, Martuza RL, Montgomery WW, de Sandoval PK. Preservation of hearing in surgical removal of acoustic neuromas of the internal auditory canal and cerebellar pontine angle. Laryngoscope 1987 Nov; 97(11): l287-94. 35. Seizinger BR, Martuza RL, Rouleau G, Breakefield XO, Gusella JF. Models for inherited susceptibility to cancer in the nervous system: A molecular-genetic approach to neurofibromatosis. Develop Neurosci 1987; 9(3): 144-53. 36. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, Haines J, Yuen JWM, Collins D, Majoor-Krakuer D, Bonner T, Mathew C, Rubenstein A, Halperin J, McConkie-Rosell A, Green JS, Trofatter JA, Ponder BA, Eierman L, Bowmer MI, Schimke R. Oostra B, Aronin N, Smith DI, Drabkin H, Waziri MH, Hobbs WJ, Martuza RL, Conneally PM, Hsia YE, Gusella JF. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988 Mar 17; 332: 268-9. 37. Kostron H, Swartz MR, Martuza RL. Photodynamic therapy is potentiated by Co60 and intratumoral injection of hematoporphyrin derivative. J Neuro-oncol 1988 Sep; 6(2): 185-91. 38. Seizinger BR, Farmer GE. Haines JL. Ozelius LJ. Anderson K. Korf BR. Parry DM. Pericak-Vance MA. Mulvihill JJ. Menon A. Hobbs WJ. Martuza RL. Gusella JF. Flanking markers for the gene causing von Recklinghausen neurofibromatosis (NF-l). Amer J Hum Gen 1989 Jan; 44(1): 30-2. 39. el-Azouzi M, Chung RY, Farmer GE, Martuza RL, Black, PL, Rouleau GA, Hettlich C, Hedley- Whyte ET, Zervas NT, Panagopoulos K, Nakamura Y, Gusella JF, Seizinger BR. Loss of distinct regions on the short arm of chromosome 17 associated with tumorigenesis of human astrocytomas. Proc Nat Acad Sci USA 1989 Sep; 86(18): 7186-90. 40. Medhkour A, Van Roey M, Sobel RA, Fingert HJ, Lee J, Martuza RL. Implantation of human meningiomas into the subrenal capsule of the nude mouse: A model for studies of tumor growth. J Neurosurg 1989 Oct; 71(4): 545-50. 41. Louis DN, Hedley-Whyte ET, Martuza RL. Sarcomatous proliferation of the vasculature in a subependymoma. Acta Neuropath 1989; 78(3): 332-5. 42. Rouleau GA, Seizinger BR, Wertelecki W, Haines JL, Superneau DW, Martuza RL, Gusella JF. Flanking markers bracket the neurofibromatosis type 2 (NF2) gene on chromosome 22. Amer J Hum Gen 1990 Feb; 46(2): 323-8. 43. Logan JA, Seizinger BR, Atkins L, Martuza RL. Loss of the Y chromosome in meningiomas: a molecular genetic approach. Canc Gen & Cytogen 1990 Mar; 45(1): 41-7. 44. Lee JK, Kim TS, Chiocca EA, Medhkour A, Martuza RL. Growth of human Schwannomas in the subrenal capsule of the nude mouse. Neurosurg 1990Apr; 26(4): 598-605. 45. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, Farmer GE, Freiman RN, Lee JK, Li FP, Barker DF, Ledbetter DH, Kleider A, Martuza RL, Gusella JF, Seizinger BR. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Nat Acad Sci USA 1990 Jul; 87(14): 5435-9. 46. Chiocca EA, Choi BB, Cai W, DeLuca NA, Schaffer PA, DiFiglia M, Breakefield XO, Martuza RL. Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New Biologist 1990 Aug; 2(8): 739-46. 14
  15. 15. 47. Lee JK, Choi B, Sobel RA, Chiocca EA, Martuza RL. Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone. J Neurosurg 1990 Sep; 73(3): 429-35. 48. Steichen JD, Stewart RB, Louis DN, Choi BB, Kung R, Martuza RL. A new 1.9 micron wavelength laser for neurosurgery. J Neurosurg 1990 Oct; 73(4): 611-4. 49. Jacoby LB, Pulaski K, Rouleau GA, Martuza RL. Clonal analysis of human meningiomas and schwannomas. Canc Res 1990 Nov 1; 50(21): 6783-6. 50. Fontaine B, Rouleau GA, Seizinger BR, Jewell AF, Hanson MP, Martuza RL, Gusella JF. Equal parental origin of chromosome 22 losses in human sporadic meningioma: No evidence for genomic imprinting. Amer J Hum Gen 1990 Nov; 47(5): 823-7. 51. Jacoby LB, Hedley-Whyte ET, Pulaski K, Seizinger BR, Martuza RL. Clonal origin of pituitary adenomas. J Neurosurg 1990 Nov; 73(5): 731-5. 52. Short MP, Choi BB, Lee JK, Malick A, Breakefield XO, Martuza RL. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res 1990 Nov; 27(3): 427-39. 53. Louis DN, Hedley-Whyte TE, Martuza RL. Sarcomatous proliferation of the vasculature in a subependymoma: A follow-up study of sarcomatous dedifferentiation. Acta Neuropath 1990; 80(5): 573-4. 54. Steichen JD, Weiss MJ, Elmaleh DR, Martuza RL. Enhanced in vitro uptake and retention of 3 H-tetraphenylphosphonium by nervous system tumor cells. J Neurosurg 1991 Jan; 74(1): 116-22. 55. Fontaine B, Hanson MP, VonSattel JP, Martuza RL, Gusella JF. Loss of chromosome 22 alleles in human sporadic spinal schwannomas. Ann Neurol 1991 Feb; 29(2): 183-6. 56. Halliday AL, Sobel RA, Martuza RL. Benign spinal nerve sheath tumors: Their occurrence sporadically and in neurofibromatosis types 1 and 2. J Neurosurg 1991 Feb; 74(2): 248-53. 57. Seizinger BR, Smith DI, Filling-Katz MR, Neumann H, Green JS, Choyke PL, Anderson KM, Freiman RN, Klauck SM, Whaley J, Decker H-JH, Hsia YE, Collins D, Halperin J, Lamiell JM, Oostra B, Waziri MH, Gorin MB, Scherer G, Drabkin HA, Aronin N, Schinzel A, Martuza RL, Gusella JF, Haines JL. Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of von Hippel Lindau disease. Proc Nat Acad Sci USA 1991 Apr; 88(7): 2864-8. 58. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991 May 10; 252(5007): 854-6. 59. Fontaine B, Sanson M, Delattre O, Menon AG, Rouleau GA, Seizinger BR, Jewell AF, Hanson MP, Aurias A, Martuza RL, Gusella JF, Thomas G. Parental origin of chromosome 22 loss in sporadic and NF2 neuromas. Genomics 1991 May; 10(1): 280-3. 60. Ezzedine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B, Breakefield XO. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biologist 1991 Jun; 3(6): 608-14. 61. Jenike MA, Baer L, Ballantine HT, Martuza RL, Tynes S, Giriunas I, Buttolph ML, Cassem NH. Cingulotomy for refractory obsessive-compulsive disorder: A long-term follow-up of 33 patients. Arch Gen Psych 1991 Jun; 48(6): 548-55. 62. Chung RY, Whaley JM, Kley N, Anderson KM, Louis D, Menon A, Hettlich C, Freiman R, Hedley-Whyte ET, Martuza RL, Jenkins R, Yandell DW, Seizinger BR. TP53 gene mutations and 17p deletions in human astrocytomas. Genes, Chromosomes, and Cancer 1991 Sep; 3(5): 323-31. 63. Flexon PB, Nadol JB Jr, Schuknecht HF, Montgomery WW, Martuza RL. Bilateral acoustic neurofibromatosis (neurofibromatosis 2): a disorder distinct from Von Recklinghausen’s neurofibromatosis (neurofibromatosis 1). Ann Otol Rhinol Laryngol 1991 Oct; 100(10): 830-4. 15
  16. 16. 64. Fontaine B, Rouleau GA, Seizinger BR, Menon AG, Jewell AF, Martuza RL, Gusella JF. Molecular genetics of neurofibromatosis 2 and related tumors (acoustic neuroma and meningioma). Ann NY Acad Sci 1991; 615: 338-43. 65. Huang Q, VonSattel JP, Schaffer PA, Martuza RL, Breakefield XO, DiFiglia M. Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: A light and electron microscopic study. Exper Neurol 1992 Mar; 115(3): 303-16. 66. Poon WS, Schomacker KT, Deutsch TF, Martuza RL. Laser-induced fluorescence: Experimental intraoperative delineation of tumor resection margins. J Neurosurg 1992 Apr; 76: 679-86. 67. von Deimling A, Louis DN, von Ammon K, Petersen I, Hoell T, Chung RY, Martuza RL, Schoenfield DA, Yasargil MG, Wiestler OD, Seizinger BR. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 1992 Aug; 77(2): 295-301. 68. Narod SA, Parry DM, Parboosingh J, Lenoir GM, Ruttledge M, Fischer G, Eldridge R, Martuza RL, Frontali M, Haines J, Gusella JF, Rouleau GA. Neurofibromatosis type 2 appears to be a genetically homogeneous disease. Amer J Hum Genet 1992 Sep; 51(3): 486-96. 69. Lee JK, Sobel RA, Chiocca EA, Kim TS, Martuza RL. Growth of human acoustic neuromas, neurofibromas and shwannomas in the subrenal capsule and sciatic nerve of the nude mouse. J Neuro-Oncol 1992 Oct; 14(2): 101-12. 70. Markert JM, Coen DM, Malick A, Mineta T, Martuza RL. Expanded spectrum of viral therapy in the treatment of nervous system tumors. J Neurosurg 1992 Oct; 77(4): 590-4. 71. Nadol JB Jr, Chiong CM, Ojemann RG, McKenna MJ, Martuza RL, Montgomery WW, Levine RA, Ronner SF, Glynn RJ. Preservation of hearing and facial nerve function in resection of acoustic neuroma. Laryngoscope 1992 Oct; 102(10): 1153-8. 72. Takamiya Y, Short MP, Ezzedine ZD, Moolten FL, Breakefield XO, Martuza RL. Gene therapy of malignant brain tumors: A rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res 1992 Nov; 33(3): 493- 503. 73. Martuza RL. Molecular Neurosurgery for glial and neuronal disorders. Stereotac & Funct Neurosurg 1992; 59(1-4): 92-9. 74. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, Haase VH, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short MP, Buckler AJ, Gusella JF. A novel Moesin-, Ezrin-, Radixin-like gene is a candidate for the Neurofibromatosis 2 tumor suppressor. Cell 1993 Mar 12; 72(5): 791-800. 75. Takamiya Y, Friedlander RM, Brem H, Malick A, Martuza RL. Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470. J Neurosurg 1993 Mar; 78(3): 470-6. 76. Markert JM, Malick A, Coen DM, Martuza RL. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurg 1993 Apr; 32(4): 597-603. 77. Yu JS, Wei MX, Chiocca EA, Martuza RL, Tepper RI. Treatment of glioma by engineered interleukin 4-secreting cells. Canc Res 1993 Jul 1; 53(13): 3152-8. 78. Takamiya Y, Short MP, Moolten FL, Fleet C, Mineta T, Breakefield XO, Martuza RL. An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg 1993 Jul; 79(1): 104-10. 79. Baer L, Rauch SL, Jenike MA, Cassem NH, Ballantine HT, Manzo PA, Martuza RL. Cingulotomy in a case of concomitant obsessive-compulsive disorder and Tourette’s syndrome. Arch Gen Psych 1994 Jan; 51(1): 73-4. 16
  17. 17. 80. Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza RL. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurg 1994 May; 34(5): 869-75. 81. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir- hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Canc Res 1994 Aug 1; 54(15): 3963-6. 82. al-Nabulsi I, Takamiya Y, Voloshin Y, Dritschilo A, Martuza RL, Jorgensen TJ. Expression of thymidine kinase is essential to low dose radiation resistance of rat glioma cells. Canc Res 1994 Nov 1; 54(21): 5614-7. 83. Ahmad S, Mineta T, Martuza RL, Glazer RI. Antisense expression of protein kinase Cα inhibits the growth and tumorigenicity of human glioblastoma cells. Neurosurg 1994 Nov; 35(5): 904-8; discussion 908-9.. 84. Mineta T, Markert JM, Takamiya Y, Coen DM, Rabkin SD, Martuza RL. CNS tumor therapy by attenuated herpes simplex viruses. Gene Ther 1994; 1 Suppl 1: S78. 85. New KC, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors for the study of promoter and gene function in the CNS. Gene Ther 1994; 1 Suppl 1: S79. 86. Baer L, Rauch SL, Ballantine HT Jr, Martuza RL, Cosgrove R, Cassem E, Giriunas I, Manzo PA, Dimino C, Jenike MA. Cingulotomy for intractable obsessive-compulsive disorder: Prospective long-term follow-up of 18 patients. Arch Gen Psych 1995 May; 52(5): 384-92. 87. Mineta T, Tabuchi K, Martuza RL. Gene therapy for brain tumors: Experimental treatment of malignant brain tumors using recombinant herpes simplex virus type 1 (series 7). No Shinkei Geka – Neurolog Surg 1995 Sep; 23(4): 285-92. 88. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med 1995 Sep; 1(9): 938-43. 89. Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Canc Res 1995 Nov 1; 55(21): 4752-6. 90. Yazaki T, Takamiya Y, Costello PC, Mineta T, Menon AG, Rabkin SD, Martuza RL. Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470. J Neuro-oncol 1995; 23(1): 23-9. 91. Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL, Glazer RI. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-α phosphorothioate oligodeoxynucleotide. Molec Pharmacol 1996 Aug; 50(2): 236-42. 92. Yazaki T, Martuza RL, Rabkin SD. Expression of L1 in primary astrocytes via a defective herpes simplex virus vector promotes neurite outgrowth and neural cell migration. Molec Brain Res 1996 Dec 31; 43(1-2): 311-20. 93. Menon AG, Rutter JL, VonSattel JP, Snyder H, Murdoch C, Blumenfeld A, Martuza RL, von Deimling A, Gusella JF, Houseal TW. Frequent loss of chromosome 14 in atypical and malignant meningioma: Identification of a putative ‘tumor progression’ locus. Oncogene 1997 Feb 6; 14(5): 611-6. 94. Miyatake S, Iyer A, Martuza RL, Rabkin SD. Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol 1997 Jul; 71(7): 5124-32. 95. Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Canc Gene Ther 1997 Jul-Aug; 4(4): 222-8. 96. Toda M, Martuza RL, Kojima H, Rabkin SD. In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor immunity. J Immunol 1998 May 1; 160(9): 4457-64. 17
  18. 18. 97. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998 Oct 10; 9(15): 2177-85. 98. New KC, Gale K, Martuza RL, Rabkin SD. Novel synthesis and release of GABA in cerebellar granule cell cultures after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase. Molec Brain Res 1998 Oct 30; 61(1-2): 121-35. 99. Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999 Feb 10; 10(3): 385-93. 100.Miyatake SI, Tani S, Feigenbaum F, Sundaresan P, Toda H, Narumi O, Kikuchi H, Hashimoto N, Hangai M, Martuza RL, Rabkin SD. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther 1999 Apr; 6(4): 564-72. 101.Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999 Jun; 1(2): 162-9. 102.Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT, Platenberg RC, Manz HJ, Rabkin SD. Attenuated, replication-competent, herpes simplex virus type-1 mutant G207: Safety evaluation of intracerebral injection in non-human primates. J Virol 1999 Aug; 73(8): 6319-26. 103.Walker JR, McGeagh K, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999, Sep 1;10(13): 2237-43. 104.Mashour GA, Wang HL, Cabal-Manzano R, Wellstein A, Martuza RL, Kurtz A. Aberrant cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type- 1. J Invest Dermatol 1999 Sep; 113(3): 398-402. 105.Chahlavi A, Rabkin SD, Todo T, Sundaresan P, Martuza RL. Effect of prior exposure to HSV-1 on viral vector mediated tumor therapy in immunocompetent mice. Gene Ther 1999 Oct; 6(10): 1751-8. 106.Todo T, Rabkin SD, Chahlavi A, Martuza RL. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum Gene Ther 1999 Nov 20; 10(17): 2869-78. 107.Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB, Martuza RL. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication- competent herpes simplex virus. Hum Gene Ther 1999 Nov 20; 10(17): 2741-55. 108.Mashour GA, Martuza RL, Kurtz A. Induction of melanogenic abnormalities in NF1+/- mutant mice by DMBA. J Invest Dermatol 1999 Dec; 113(6): 1133-4. 109.Sandhu FA, Schellinger D, Martuza RL. A vascular sarcoid mass mimicking a convexity meningioma. Neuroradiol 2000 Mar; 42(3): 195-8. 110.Sundaresan P, Hunter WD, Martuza RL, Rabkin SD. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation in mice. J Virol 2000 Apr; 74(8): 3832-41. 111.Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 2000 May; 7(10): 867-74. 112.Todo T, Rabkin SD, Martuza RL. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Canc Gene Ther 2000 Jun; 7(6): 939-46. 18
  19. 19. 113.Lim DJ, Rubenstein AE, Evans DG, Jacks T, Seizinger BG, Baser ME, Beebe D, Brackmann DE, Chiocca EA, Fehon RG, Giovanni M, Glazer R, Gusella JF, Gutmann DH, Korf B, Lieberman F, Martuza RL, McClathey AI, Parry DM, Pulst SM, Ramesh V, Ramsey WJ, Ratner N, Rutkowski JL, Ruttledge M, Weinstein DE. Advances in neurofibromatosis 2 (NF2): a workshop report. J Neruogenet, 200 Jun: 14(2):63-106. Review. 114.Moulding HD, Martuza RL, Rabkin SD. Clinical mutations in the L1 neural cell adhesion molecule affect cell-surface expression. J Neurosci 2000 Aug 1; 20(15): 5696-702. 115.Toda M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Molec Ther 2000 Oct; 2(4): 324-9. 116.Todo T, Feigenbaum F, Rabkin SD, Lakeman F, Newsome JT, Johnson PA, Mitchell E, Belliveau D, Ostrove JM, Martuza RL. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Molec Ther 2000 Dec; 2(6): 588-95. 117.Sandhu FA, Martuza RL. Craniofacial hemangiopericytoma associated with oncogenic osteomalacia: Case report. J Neuro-oncol 2000; 46(3): 241-7. 118.Todo T, Martuza RL, Dallman MJ, Rabkin SD. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Canc Res 2001 Jan 1; 61(1): 153-61. 119.Mashour GA, Ratner N, Khan GA, Wang HL, Martuza RL, Kurtz A. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 2001 Jan 4; 20(1): 97-105. 120.Toda M, Martuza RL, Rabkin SD. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther 2001 Feb; 8(4): 332-9. 121.Wu A, Mazumder A, Martuza RL, Liu X, Thein M, Meehan KR, Rabkin SD. Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Canc Res 2001 Apr; 61(7): 3009-15. 122.Varghese S, Newsome JT, Rabkin SD, McGeagh K, Mahoney D, Nielsen P, Todo T, Martuza RL. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type I, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther 2001 May 20; 12(8): 999-1010. 123.Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Nat Acad Sci USA 2001 May 22; 98(11): 6396-401. 124.Mashour GA, Moulding HD, Chahlavi A, Khan GA, Rabkin SD, Martuza RL, Driever PH, Kurtz A. Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model. Exper Neurol 2001 May; 169(1): 64-71. 125.Jorgensen TJ, Katz S, Wittmack EK, Varghese S, Todo T, Rabkin SD, Martuza RL. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia (New York) 2001 Sep-Oct; 3(5): 451-6. 126.Kurtz A, Martuza RL. Antiangiogenesis in neurofibromatosis 1. J Child Neurol 2002 Aug; 17(8): 578-84. 127.Nikolic B, Feigenbaum F, Abbara S, Martuza RL. Schellinger D. CT changes of an intracranial granulocytic sarcoma on short-term follow-up. Amer J Roentgenol 2003 Jan; 180(1): 78-80. 19
  20. 20. 128.Weber DC, Chan AW, Bussiere MR, Harsh GR 4th, Ancukiewicz M, Barker FG 2nd, Thornton AT, Martuza RL, Nadol JB Jr, Chapman PH, Loeffler JS. Proton beam radiosurgery for vestibular schwannoma: Tumor control and cranial nerve toxicity. Neurosurg 2003 3Sep; 53(3): 577-86. 129.Mashour GA, Driever PH, Hartmann M, Drissel, SN, Shang T, Schart B, Fedlerhoff-Muser U, Sakuma S, Friedrich RE, Martuza RL, Mautner V-F, Kurtz A. Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis Type 1. Clin Cancer Research. 2004 Sept, 5677-5683. 130. Liu, R, Martuza RL, Rabkin SD., Intracarotid Delivery of Oncolytic HSV Vector G47∆ To Metastatic Breast Cancer in the Brain. Gene Therapy 2005 Apr 12(8):647-654. 131.Mashour GA, Drissel SN, Frahm S, Farassati F, Martuza RL, Mautner V-F, Kindler-Rohrborn A, Kurtz A., Differential Modulation of Malignant Peripheral Nerve Sheath Tumor Growth by Omega-3 and Omega-6 Fatty Acids. Oncogene. 2005 Mar 31; 24(14):2367-74. 132.Kurtz A, Lueth M, Kluwe L, Shang T, foster R, Mautner VF, Hartmann M, Tan DJ, Martuza RL, Friedrich RE, Driever Ph, Won Lj., Somatic mitochonrial DNA mutations in neurofibromatosis type 1-associated tumors. Mol Cancer Res., 2004 Aug;2(8):433-41. 133.Doolittle ND, Abrey LE, Bleyer WA, Brem S, Davis TP, Dore-Duffy P, Drewes LR, Hall WA, Hoffman JM, Korfel A, Martuza R, Muldoon LL, Peereboom D., Peterson DR, Rabkin SD, Smith Q, Stevens, GHJ, Neuwelt EA. New Frontiers in Translational Research in Neuro-oncology and the Blood Brain Barrier: Report of the Tenth Annual Blood-Brain Barrier Disruption consortium Meeting, Clin Canc Res, 2005 Jan; (11):421-28. 134.Mashour GA, Walker EE, Martuza RL. Psychosurgery: past, present, and future. Brain Res Brain Res Rev. 2005 Jun;48(3):409-19. 135.Chan AW, Black P, Ojemann RG, Barker FG 2nd , Kooy HM, Lopes VV, McKenna MJ, Shrieve DC, Martuza RL, Loeffler JS. Stereotactic radiotherapy for vestibular schwannomas: favorable outcome with minimal toxicity. Neurosurgery. 2005 Jul;57(1):60-70; discussion 60-70. 136.Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RI. Enhanced therapeutic efficiacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Therapy, 2005 Sept, (Advance Online Publication) 137.Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin Cancer Res. 2005 Nov 1;11(21):7886-90. 138.Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res. 2005 Dec 1;65(23):10663-8. 139. Lui R, Martuza RL, Rabkin SD. Intracarotid delivery of oncolytic HSV vector G47∆ to metastatic breast cancer in the brain, Gene therapy 2005 12, 647-654. 140.Aghi M, Rabkin S, Martuza RL. The effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. Journal of the National Cancer Institute, J Natl Cancer Inst. 2006 Jan 4;98(1):38-50. 141.Varghese S Rabkin SD, Nielsen PG, Wang W, and Martuza RL. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clinical Cancer Research (in press) 142.Messerli SM, Prabhakar S, Tang Y, Mahmood U, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO. Treatment of Schwannomas with an Oncolytic Recombinant Herpes Simplex Virus in Murine Models of Neurofibromatosis Type 2. Hum Gene Ther. 2006 Jan 17: 20-30. 20
  21. 21. Books, Chapters, Monographs, Reviews, Other Publications 1. Martuza RL, Ojemann RG. Intracranial neoplasms. In Current Diagnosis. (Conn HF and Conn RB Jr). WB Saunders Co., Philadelphia. 13: 895-902, 1980. 2. Martuza RL. Neurofibromatosis: neurological and neurosurgical considerations. Neurology and Neurosurgery Update Series. Continuing Professional Education Center, Inc. 38(3), l982. 3. Martuza RL. Genetics in neuro-oncology. Clin Neurosurg. 31: 4l7-40, 1984. 4. Martuza RL. Neurofibromatosis and other phakomatoses. In Neurosurgery (Wilkins RH and Rengachary SS). McGraw-Hill Book Co., NY. II(55): 511-21, 1984. 5. Martuza RL. Genetic factors in brain tumors. In Neurosurgery (Wilkins RH and Rengachary SS). McGraw-Hill Book Co., NY. II(54): 505-ll, 1984. 6. Martuza RL. Parker SW. Nadol JB Jr. Davis KR. Ojemann RG. Diagnosis of cerebellopontine angle tumors. Clin Neurosurg. 32: l77-2l3, 1985. 7. Martuza RL. Aquino T. Trauma. In Manual of Neurologic Therapeutics, Third Edition (Samuels MA). Little, Brown, Co. Boston, MA. 1985. 8. Martuza RL. Seizinger BR. Jacoby LB. Rouleau GA. Gusella JF. The molecular biology of human glial tumors. Trends in Neurosciences. 11(1): 22-7, 1988 Jan. 9. Martuza RL. Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). New England Journal of Medicine. 318(11): 684-8, 1988 Mar 17. 10. Martuza RL. Neurosurgical aspects of neurofibromatosis. In Neurofibromatosis. In A Handbook for Patients, Families, and Health Care Professionals (Rubenstein A and Korf B). Thieme-Stratton Pub. Co. 11. Ojemann RG. Martuza RL. Acoustic neuroma. In Neurological Surgery, Third Edition (Youmans J). WB Saunders Co., Philadelphia. Ch 113; 3316-50, 1990. 12. Chiocca EA. Martuza RL. Neurosurgical therapy of the obsessive-compulsive disorder. In Obsessive Compulsive Disorders: Theory and Management, Second Edition (Jenike M, Baer L and Minichiello WE). Year Book Medical Publishers, Inc., Chicago. 1990. 13. Fontaine B. Rouleau GA. Seizinger BS. Menon AG. Jewell AF. Martuza RL. Gusella JF. Molecular genetics of neurofibromatosis 2 and related tumors (acoustic neuroma and meningioma). Ann NY Acad Sci. 615: 338-343, 1990. 14. Martuza RL. Rouleau G. Genetic aspects of neurosurgical problems. In Neurological Surgery, Third Edition (Youmans J). WB Saunders Co., Philadelphia. Ch 38; 1061-1080, 1990. 15. Steichen JD. Martuza RL. Trauma. In Manual of Neurologic Therapeutics, Fourth Edition (Samuels MA). Little, Brown, Co., Boston, MA. 1990. 16. Eldridge R. Martuza RL. Parry DM. Neurofibromatosis 2. In Current Therapy in Neurologic Disease. (Johnson RT). B.C. Decker Inc., Philadelphia. 1990. 17. Martuza RL. Chiocca EA. Jenike MA. Giriunas I, Ballantine HT. Stereotactic radiofrequency thermal cingulotomy for obsessive-compulsive disorder. J of Neuropsychiatry and Clinical Neurosciences. 2(3): 331-6, 1990 Summer. 18. Martuza RL. Neurofibromatosis as a model for tumor formation in the human nervous system. Neurobiology of Brain Tumors. Concepts in Neurosurgery. 4: 53-62, 1991. 19. Gusella JF. Seizinger BR. Rouseau G. Menon A. Fontaine B. Martuza RL. Molecular genetic analysis of the phakomatoses. In Molecular Mechanisms and Their Clinical Applications in Malignancies. Academic Press, Inc. 1991. 20. Martuza RL. Pathogenesis and treatment of nervous system tumors in NF2. In Tuberous 21
  22. 22. sclerosis and Neurofibromatosis: Epidemiology, Pathophysiology, Biology, and Management (Ishibashi Y and Hori E). Elsevier Science Publishers B.V., Amsterdam. 1991. 21. Martuza RL. Genetic alterations of nervous system tumors. In Biologic Aspects of Brain Tumors (Tabuchi). Springer-Verlag Inc., Tokyo. 18-27, 1991. 22. Short MP. Martuza RL. Clinical and genetic aspects of NF2: clinical features, family studies, counseling, and management issues. In Neurofibromatosis (Hughes RAC and Huson ). Chapman and Hall Ltd, London. 1991. 23. Martuza RL. Viral vectors for experimental brain tumor therapy. In Molecular Genetics of Nervous System Tumors (Levine A and Schmidek H). 381-386. 24. Chiocca EA. Andersen JK. Takamiya Y. Martuza RL. Breakefield XO. Virus-mediated genetic treatment of rodent gliomas. Gene Therapeutics (Wolff JA). Birkhauser Publishers, Boston. 245-63, 1994. 25. Baer L. Rauch AL. Ballantine HT Jr. Martuza RL. Cosgrove R. et al. Cingulotomy for intractable obsessive-compulsive disorder: prospective long-term follow-up of 18 patients. Arch Gen Psych. 52(5): 384-92, 1995 May. 26. Hunter W. Rabkin S. Martuza RL. Brain tumor therapy using genetically engineered replication competent virus. In Viral Vectors (Kaplitt MG and Loewy AD). Academic Press, Inc., San Diego. 259-7, 1995. 27. Martuza RL. Proctor MR. Trauma. Manual of Neurologic Therapeutics (Samuels MA). Little, Brown, Co., Boston, MA. 5th revised edition: 250-76, 1995. 28. Viola JJ. Martuza RL. Gene therapies for glioblastomas. In Ballieres Clinical Neurology, Cerebral Gliomas (Yung WKA). 5(2): 413-24, 1996 Jun. 29. Sampson JH. Martuza RL. Genetic factors in brain tumors. In Neurosurgery, Second Edition (Wilkins RH and Rengachary SS). McGraw-Hill, New York. 665-71, 1996. 30. Sampson JH. Martuza RL. Neurofibromatosis and other phakomatoses. In Neurosurgery, Second Edition (Wilkins RH and Rengachary SS). McGraw-Hill, New York. 673-685, 1996. 31. Hunter W. Yazaki T. Rabkin SD. Martuza RL. Replication-competent viral therapy of tumors of the central nervous system. In Protocols for Gene Transfer in Neuroscience: Towards Gene Therapy of Neurological Disorders (Lowenstein P and Enquist). Wiley and Sons Ltd. 305-17, 1997. 32. Martuza RL. Act locally, think globally. Nature Medicine. 3(12): 1323, 1997 Dec. 33. Lin TS. Martuza RL. Neurofibromatosis and other dysgenetic disorders. Handbook of Clinical Neurology: Neuro-Oncology, Part II (Vecht ChJ). Elsevier Science B.V. 24(68): 1997. 34. Baidas S. Martuza RL. Tumors of the brain and spinal cord. Encyclopedia of Neuroscience. Elsevier Science. 1998. 35. Martuza RL. Coumans JV CE. Trauma: Severe head Injury, Spinal Cord Injury. In Manual of Neurologic Therapeutics, Sixth Edition (Samuels MA). Lippincott Williams & Wilkins, Philadelphia, PA. Ch 12: 285-314, 1999. 36. Lin T. Martuza RL. Gliomas in neurofibromatosis and other phakomatoses. In The Gliomas (Berger MS and Wilson C). W.B. Saunders Co., Philadelphia, PA. 15-24: 1999. 37. Feigenbaum F. Manz HJ. Platenberg LC. Martuza RL. Primary intrinsic tumors of the Brain. In Principles of Neurosurgery (Grossman RG and Loftus CM). Lippincott-Raven Publishers, Philadelphia, PA. 469-520: 1999. 38. Hunter WD. Martuza RL. Meningioma. Encyclopedia of Neuroscience. Elsevier Science. 1999. 39. Martuza RL. Conditionally-replicating herpes vectors for cancer therapy. J Clin Invest. 105(7): 841-6, 2000 Apr. 22
  23. 23. 40. Kirn D. Martuza RL. Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nature Medicine. 7(7): 781-7, 2001 Jul. 41. Mashour GA,. Walker EE, Martuza RL,. Psychosurgery: Past, Present, and Future., Brain Res Reviews. 48:409-419, 2005 42. Doolittle ND, Abrey LE, Bleyer WA, Brem S, Davis TP, Dore-Duffy P, Drewes LR, Hall WA, Hoffman JM, Korfel A, Martuza R, Muldoon LL, Peereboom D, Peterson DR, Rabkin SD, Smith Q, Stevens GH, Neuwelt EA. New frontiers in translational research in neuro- oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res 2005 Jan 15; 11: 421-428, '05 43. Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene. 2005 Nov 21;24(52):7802-16. (1/29/2015) 23